ProShare Advisors
ADVM

ProShare Advisors’s Adverum Biotechnologies ADVM Stock Holding History

ProShare Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,644
Closed -$34K – 1793
2022
Q1 		$34K Sell
2,644
-636
-19% -$9.31K ﹤0.01% 2141
2021
Q4 		$57K Buy
3,280
+71
+2% +$1.42K ﹤0.01% 2268
2021
Q3 		$70K Sell
3,209
-804
-20% -$20.5K ﹤0.01% 1948
2021
Q2 		$140K Buy
4,013
+285
+8% +$15.4K ﹤0.01% 2231
2021
Q1 		$368K Buy
3,728
+252
+7% +$30.3K ﹤0.01% 1669
2020
Q4 		$377K Buy
3,476
+879
+34% +$109K ﹤0.01% 1450
2020
Q3 		$268K Buy
2,597
+321
+14% +$48.1K ﹤0.01% 1250
2020
Q2 		$475K Buy
2,276
+1,026
+82% +$182K ﹤0.01% 970
2020
Q1 		$122K Sell
1,250
-878
-41% -$102K ﹤0.01% 1058
2019
Q4 		$245K Sell
2,128
-232
-10% -$20.4K ﹤0.01% 1461
2019
Q3 		$129K Sell
2,360
-68
-3% -$7.66K ﹤0.01% 1516
2019
Q2 		$289K Sell
2,428
-300
-11% -$24.8K ﹤0.01% 1263
2019
Q1 		$143K Buy
2,728
+23
+0.9% +$930 ﹤0.01% 1532
2018
Q4 		$85K Buy
+2,705
New +$110K ﹤0.01% 1492
2016
Q4 		– Sell
-2,834
Closed -$116K – 1741
2016
Q3 		$116K Sell
2,834
-516
-15% -$19.6K ﹤0.01% 1407
2016
Q2 		$106K Buy
3,350
+1,217
+57% +$55K ﹤0.01% 1518
2016
Q1 		$110K Sell
2,133
-223
-9% -$12.5K ﹤0.01% 1507
2015
Q4 		$224K Buy
2,356
+211
+10% +$18.5K ﹤0.01% 1475
2015
Q3 		$177K Sell
2,145
-142
-6% -$18.1K ﹤0.01% 1333
2015
Q2 		$371K Buy
2,287
+114
+5% +$38.5K 0.01% 1220
2015
Q1 		$880K Buy
2,173
+537
+33% +$227K 0.01% 906
2014
Q4 		$883K Buy
+1,636
New +$631K 0.01% 920

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ProShare Advisors's ADVM Position: Q2 2022 in Review

ProShare Advisors sold out of Adverum Biotechnologies (ADVM) in Q2 2022, closing a stake of 2,644 shares — an estimated $34K sold.

ProShare Advisors first reported a position in ADVM in Q4 2014 and held it in 22 quarters. The position peaked at $883K in Q4 2014. 77 funds tracked by Wall St. Rank hold ADVM as of Q2 2022.

  • ProShare Advisors reported no remaining Adverum Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 2,644 Adverum Biotechnologies shares in Q2 2022, an estimated $34K.
  • ProShare Advisors first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 22 quarters.
  • ProShare Advisors's Adverum Biotechnologies position peaked at $883K in Q4 2014.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.